

NIH Public Access

Author Manuscript

J Neurosci. Author manuscript; available in PMC 2013 October 03.

Published in final edited form as:

J Neurosci. 2013 April 3; 33(14): 6143–6153. doi:10.1523/JNEUROSCI.5399-12.2013.

The p38α MAPK regulates microglial responsiveness to diffuse traumatic brain injury

Adam D. Bachstetter¹, Rachel K. Rowe^{2,3}, Machi Kaneko¹, Danielle Goulding¹, Jonathan Lifshitz^{4,5,6}, and Linda J. Van Eldik^{1,2,3,*}

¹Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA, 40536

²Department of Anatomy and Neurobiology, University of Kentucky, Lexington, KY, USA, 40536

³Spinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY, USA, 40536

⁴Barrow Neurological Institute at Phoenix Children's Hospital, Phoenix, AZ, USA, 85004

⁵Department of Child Health, University of Arizona College of Medicine, Phoenix, AZ, USA, 85004

⁶Phoenix Veteran Affairs Healthcare System, Phoenix, AZ, USA, 85004

Abstract

Neuropathology following traumatic brain injury (TBI) is the result of both the immediate impact injury and secondary injury mechanisms. Unresolved post-traumatic glial activation is a secondary injury mechanism that contributes to a chronic state of neuroinflammation in both animal models of TBI and human head injury patients. We recently demonstrated, using in vitro models, that p38a MAPK signaling in microglia is a key event in promoting cytokine production in response to diverse disease-relevant stressors and subsequent inflammatory neuronal dysfunction. From these findings, we hypothesized that the p38a signaling pathway in microglia could be contributing to the secondary neuropathologic sequelae following a diffuse TBI. Mice where microglia were p38a deficient (p38a KO) were protected against TBI induced motor deficits and synaptic protein loss. In wild type (WT) mice, diffuse TBI produced microglia morphological activation that lasted for at least 7 days; however, p38a KO mice failed to activate this response. Unexpectedly, we found that the peak of the early, acute phase cytokine and chemokine levels was increased in injured p38a KO mice compared to injured WT mice. The increased cytokine levels in the p38a KO mice could not be accounted for by more infiltration of macrophages or neutrophils, or increased astrogliosis. By 7 days after injury, the cytokine and chemokine levels remained elevated in injured WT mice but not in p38a KO mice. Together, these data suggest that p38a balances the inflammatory response by acutely attenuating the early proinflammatory cytokine surge, while perpetuating the chronic microglia activation after TBI.

Keywords

neuroinflammation; cytokines; axonal injury; signal transduction; kinase

^{*}Corresponding author: Linda J. Van Eldik, PhD, Sanders-Brown Center on Aging, University of Kentucky, 800 S. Limestone, Lexington, KY 40536 USA, Tel.: 859-323-6040; Fax: 859-323-2866; linda.vaneldik@uky.edu. **Conflict of Interest:** None

INTRODUCTION

Traumatic brain injury (TBI) represents a spectrum of pathological conditions, which range from focal-to-diffuse, and from mild-to-severe (Saatman et al., 2008). Regardless of the cause of the injury, fundamental to the survival of the organism is a repair process that is remarkably conserved among different tissues and in response to different injuries (Gurtner et al., 2008). Inflammation is central to the classical described repair process, and as such is critical for health of the organism. However, inflammation that is inefficient, excessive, or prolonged can result in infection, edema, or reactive oxygen species and produce collateral damage, which persists after the primary injury. Therefore, understanding the role of inflammation in the multicellular repair process following a brain injury is of great medical and biological importance. The consequences of even a mild brain injury can be long-lasting and increase the risk of dementia (Uryu et al., 2007; Gavett et al., 2010; Johnson et al., 2012). Associated with the secondary disease process following a TBI is persistent microglia activation lasting for more than a decade (Ramlackhansingh et al., 2011; Giunta et al., 2012). Microglia – the resident CNS macrophage – respond within 30 minutes to a brain injury (Davalos et al., 2005; Nimmerjahn et al., 2005). Once the microglia respond to chemoattractants and damage associated molecular patterns (DAMPs), the microglia release inflammatory mediators (e.g. IL-1β, TNFa, and nitric oxide). The inflammatory mediators and DAMPs act on cytokine receptors and conserved pattern recognition receptors (e.g. Toll-like receptors) to initiate an acute phase response (Morganti-Kossmann et al., 2007; Chen and Nunez, 2010). Phenotypic subpopulations of activated microglia, based on a molecular signature of gene expression, are characterized as a classical proinflammatory state (M1 microglia) or an alternatively activated state (M2 microglia) associated with antiinflammatory and wound healing functions (Colton, 2009; David and Kroner, 2011).

Central to linking the inflammatory stimuli in microglia to the cellular response is the mitogen-activated protein kinase (MAPK) p38a. The expression of p38a is ubiquitous; however, recent studies have shown that p38a has unique functions depending on cell, tissue, and disease stimulus. In experimental autoimmune encephalomyelitis, p38a in dendritic cells, but not T-cells or macrophages, is necessary for the disease progression by regulating a TH_{17} response (Huang et al., 2012). In microglia, p38 has been shown to be important for phagocytosis of beta-amyloid and axon debris (Reed-Geaghan et al., 2009; Hosmane et al., 2012) as well as production of IL-1 β and TNFa (Bachstetter et al., 2011). However, the role of p38a in the repair process following a brain injury has not been defined. We used a diffuse brain injury model without contusion, cavitation or tissue destruction, but with profound microglia activation (Cao et al., 2012). We report here that p38a regulates the microglia morphological activation, and limits the acute phase cytokine response to the diffuse TBI.

EXPERIMENTAL PROCEDURES

Animals

The Institutional Animal Care and Use Committee of the University of Kentucky approved the use of animals in this study, which were conducted in accordance with the principles of animal care and experimentation in the Guide For the Care and Use of Laboratory Animals. To generate p38a conditional knockout mice, the first exon of the p38a gene (MAPK14) was flanked by two loxP sites, and then crossed with mice that contain Cre driven by the lysozyme promoter, as previously described (Kang et al., 2008; Bachstetter et al., 2011; Xing et al., 2011). The restricted cell-type expression of the lysozyme promoter (Clarke et al., 1996; Clausen et al., 1999) results in cell-specific deletion of p38a MAPK in myeloid cells including microglia, as previously validated (Bachstetter et al., 2011; Xing et al., 2011). The mice (all backcrossed to C57Bl/6) were maintained and bred as follows: p38a^{fl/fl}

wildtype and not carrying the Cre allele (p38a WT) were bred with Lys-Cre hemizygotes. This generates litters where ~50% of the mice are microglia/macrophage conditional p38a KO and ~50% are p38a^{fl/fl} littermates (used as WT controls). All experiments with p38a mice used both sexes of mice at ~50:50 ratio. Genotyping was performed by Transnetyx, Inc (Cordova, TN). Male C57BL/6J mice were obtained from Jackson Laboratory.

Midline fluid percussion injury (mFPI)

The animals were subjected to mFPI as previously described (Lifshitz, 2008). Briefly, 3 – 4 month old male and female mice were used for the experiment. To prepare for the mFPI, mice were anesthetized with 5% isoflurane prior to stabilizing the head using ear bars in a stereotaxic frame (David Kopf Instruments). Anesthesia was maintained with continuous inhalation of isoflurane (3.5%, 1 liter/min). A midline incision was made in the scalp to expose the skull. A 3.0mm diameter craniotomy was made using a trephine along the sagittal suture, midway between bregma and lambda. Mice were excluded from the experiment if dura was breached during the craniotomy. The top portion of the Luer-Loc hub of a 20-gauge needle (Becton Dickinson) was cut away, beveled, scored, and affixed over the craniotomy site using cyanoacrylate. Dental acrylic was applied around the hub to provide stability during the injury induction. After the dental acrylic hardened, a Luer-Loc cap was applied to the hub and sutures were applied where necessary to close the skin around the dental acrylic head stage. Mice were given 16–24 hours to recover from the craniotomy prior to injury.

Before injury, mice were anesthetized for 5 min with 5% isoflurane in a small induction chamber. Then, the Luer-loc cap was removed, and the hub was filled with normal saline, and attached to the male end of the fluid percussion device, ensuring that no air bubbles were introduced into the system. Once a normal breathing pattern resumed, before sensitivity to stimulation, a pressure pulse was generated by the fluid percussion device (Custom Design and Fabrication, Richmond, VA). An injury of moderate severity (1.2 \pm 0.05 atm) was administered by releasing the pendulum onto the fluid filled piston, moments before the reflexive responses returned. After injury, the hub assembly was removed en bloc. The injury site was inspected, and the incision was sutured. The time to right was recorded. The mice were placed in a cage with a warming pad, and monitored until normal movement and grooming resumed. Sham mice were subjected to all the experimental and surgical conditions described above, except the fluid percussion injury was not administered.

Rotarod

Personnel blinded to animal groups measured the distance mice traveled using the Rotor-Rod system from San Diego Instruments. Animals were pre-trained (60 sec at 4 RPM for 3 trials) on the rotarod for two consecutive days prior to the craniotomy. Testing began at 24 hours post-injury, and was repeated for the next six days. For the test, the animal was placed on the rod with the starting speed set to 4 RPM, and the speed was then continuously accelerated up to 25 RPM over five min. When the animal fell off the rod breaking the photo beam, the instrument recorded latency to fall and total distance traveled. Two trials were run daily for each animal, and the mean of the two trials was plotted.

Euthanasia and brain tissue harvesting

Mice were euthanized by sodium pentobarbital overdose, and transcardially perfused with ice-cold phosphate buffered saline (PBS) for 5 min. The brains were rapidly removed. On ice, the brain was bisected along the sagittal plane with one hemisphere further dissected and flash frozen in liquid nitrogen, and stored at -80° C for subsequent biochemical evaluation. The other hemisphere was immersion fixed in 4% paraformaldehyde for 14 to 16 hours, prior to cryoprotection in a 30% sucrose/PBS solution.

Biochemical endpoint analyses

For protein measurements, a PBS fraction and a detergent fraction were generated from neocortical tissue using a high shear homogenizer (Omni TH115). The PBS fraction was prepared by homogenizing the cortical tissue in a 1:10 (w/v) of ice-cold freshly prepared lysis buffer consisting of 1 μ g/ml Leupeptin, 1mM PMSF, and 1mM EDTA. The cortical homogenate was centrifuged at 12,000 × g for 20 min at 4°C in a Beckman Microfuge 18, and supernatants collected for measurement of cytokines. A detergent-solubilized fraction was prepared by re-suspending and re-homogenizing the pellet in a detergent-containing lysis buffer (tissue protein extraction reagent with Halt protease and phosphatase inhibitor cocktail: Thermo Scientific) at the same volume used for first homogenization. Homogenates were cleared by centrifugation at 12,000 × g for 20 min at 4°C, and supernatants used for measurement of synaptic proteins.

Cytokine levels were measured as previously described (Bachstetter et al., 2011; Bachstetter et al., 2012) using Meso Scale Discovery (MSD) custom multiplex high-sensitivity ELISA kits according to the manufacturer's instructions with minor modifications. Briefly, 25µl of the PBS fraction supernatant was loaded per well of the MSD plate (~100µg of protein). The sample was incubated at 4°C for ~14h. All incubation steps were done using an Eppendorf MixMate at 1000 rpm. Cytokine levels were normalized to the total amount of protein in the sample loaded as determined by BCA Protein Assay (Thermo Scientific).

Synaptic proteins levels were measured by immunoblots as previously described (Bachstetter et al., 2012). Blots were probed using reagents and manufacturer recommendations for Odyssey Infrared imaging system (LI-COR Biosciences). The detergent-solubilized fraction (1µg) was prepared in SDS buffer (LI-COR), separated on a 10% NuPAGE Novex Bis-Tris Midi Gel (Life Technologies), and transferred to nitrocellulose membrane using the iBlot® system (Life Technologies). Blots were probed with the following primary antibodies: rabbit anti-PSD95 (1:2,000, Cell Signaling, Cat no. 3450); mouse anti-synaptophysin (clone SY38) (1:30,000, Millipore, Cat no. MAB5258); rabbit anti-syntaxin 1 (1:100,000, Millipore, Cat no. ab5820), mouse anti-SNAP 25 (clone 20) (1:10,000, BD Biosciences, Cat no. 610366). Rabbit anti-GAPDH (clone 14C10) (1:10,000, Cell Signaling, Cat no. 2118) was used as a loading control. The Odyssey Infrared imaging system (LI-COR Biosciences), and integrated intensity values were used in statistics.

For gene expression, dissected neocortical tissues stored at -80 °C were used for RNA isolation using RNeasy mini-columns (Qiagen, Cat no. 74104) with on-column DNase treatment (Qiagen, Cat no. 79254) according to the manufacturer's protocol. RNA quantity and quality were determined using A260/A280 readings by NanoDrop (Thermo Scientific). Reverse transcription (RT) was done following the manufacturer's protocol using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Cat no. 4368814). A no template and a no RT control were conducted to control for contamination. Real-time PCR was performed using the TaqMan Gene Expression assay kit (Applied Biosystems, Cat no. 4444964) according to the manufacturer's instructions on a ViiA[™] 7 Real-Time PCR System (Applied Biosystems). The following TaqMan probes (Applied Biosystems) were used: IL-1ß (Mm00434228 m1); IL-6 (Mm00446190 m1); TNFa (Mm00443258 m1); CCL2 (Mm00441242_m1); CCL3 (Mm00441258_m1); CD45 (Mm01293575_m1); CD68 (Mm00839636 g1); MHCII (Mm00439216 m1); arg1 (Mm00475988 m1); YM1 (Mm00657889_mH); GLAST (Mm00600697_m1); GLT-1 (Mm00441457_m1); GFAP (Mm00546086 m1); S100B (Mm00485897 m1); VIM (Mm01333430 m1); 18S (Hs99999901_s1). Relative gene expression was calculated by the $2^{-\Delta\overline{\Delta}CT}$ method.

Immunohistochemistry (IHC)

Using a sliding microtome with a freezing stage, we collected serial coronal sections (30 µm) of the hemi brain through the entire hemisphere, and stored the sections in cryoprotectant at -20°C. Staining procedures were conducted on free-floating sections using every twelfth section through the entire hemisphere. Primary and secondary antibodies were diluted in 3% normal goat serum (NGS: LAMPIRE Biological Laboratories, Cat no. 7332500) with 0.2% Triton X-100. Endogenous peroxidase activity was quenched with 3% H₂O₂ in methanol, prior to the tissue blocking in 10% NGS with 0.2% Triton X-100. Primary antibodies used included: rabbit anti-GFAP (Dako Cat#Z0334; (1:10,000)); rabbit anti-IBA1 (Wako Cat#019-19741; (1:10,000)); rat anti-CD45 (YW62.3) (Thermo scientific Cat#MA1447081; (1:10,000)); rat anti-CD68 (Serotec Cat#MCA1957T; (1:5000)); rat anti-Ly6G/C (GR1) (BD Pharmingen Cat#550291; (1:800)); and rabbit anti-p-p38 (Cell Signaling Cat#9211; (1:1000). For the detection of GFAP and IBA1, an HRP conjugated goat anti-rabbit IgG was used. For all other primary antibodies, a biotinylated secondary antibody was amplified in avidin-biotin substrate (ABC kit, Vector Laboratories, Burlingame, CA). All sections were developed in 0.5mg/ml 3,3-diaminobenzidine tetrahydrochloride solution (Sigma, Cat#D5637). The tissue sections were dehydrated through gradients of ethyl alcohol, and finally xylene. The sections were then coverslipped with Permount Mounting Medium (Fisher Scientific).

Quantitative image analysis of IHC

As previously described (Bachstetter et al., 2012), the Aperio ScanScope XT digital slidescanner was used to image the entire stained slide at 20x magnification to create a single high-resolution digital image. The neocortex was outlined using the Aperio ImageScope software. The Aperio positive pixel count algorithm (version 9) was used to quantify the amount of specific staining in the region. The number of positive pixels was normalized to the number of total pixels (positive and negative) to account for variations in the size of the region sampled. Color and intensity thresholds were established to detect the immunostaining as positive pixels and background staining as negative pixels. To quantify the number of IBA1⁺ clusters of microglia, the Aperio nuclear algorithm (version 9). We operationally defined microglia clusters as groups of cells where the processes of the cells were overlapping, and with a total area covered by cells of greater than 1000 µm. To this end, a threshold was set in the nuclear algorithm, so only clusters of microglia larger than 1000 µm, regardless of curvature or roundness, would be quantified. We empirically found that these settings would detect multicellular groups of microglia (>4), while not detecting individual microglia. Once conditions were established for an immunohistochemical stain, the entire batch of slides was analyzed with the same parameters. The resulting color markup of the analysis was confirmed for each slide. Because of the limited number of GR1⁺ and p-p38⁺ cells, the Aperio ImageScope software was not used. GR1⁺ cells were manually counted in the cortex, and the number of cells was then averaged by the number of sections. For p-p38 quantification, 3-to-4 randomly selected fields of the neocortex from (-1.5 to -2.5mm bregma), were collected for each animal using a Nikon Eclipse 90i upright microscope equipped with a Nikon DS-Ri1 digital camera, and the number of positive cells were assessed using the Nikon Elements BR software package, according to previously described methods (Sudduth et al., 2012). Personnel blind to the experimental conditions performed all quantifications.

Statistics

Statistical analysis was conducted using GraphPad prism software V.5 (GraphPad Software, La Jolla, CA). Groups of two were compared by unpaired *t*-Test. One-way ANOVA followed by Bonferroni's multiple comparison test was used for comparisons among three

or more groups, unless otherwise indicated. Statistical significance was defined as p<0.05. Values are expressed as mean \pm SEM.

RESULTS

Myeloid-specific deletion of p38a reduces TBI-induced motor deficits

We have previously reported using *in vitro* assays that microglia p38a is critical for the production of proinflammatory cytokines and microglia mediated neuronal death (Xing et al., 2011); however, the relative *in vivo* contribution of microglia p38a to a brain injury is unknown. To test the role of microglia p38a *in vivo*, we used a model of diffuse TBI, which causes a traumatic axonal injury throughout the mediodorsal neocortex, hippocampus, and dorsolateral thalamus, without the formation of compression, contusion or tissue loss (Kelley et al., 2006; Kelley et al., 2007). There is leakage of the blood-brain-barrier in the model (Kelley et al., 2007), but the lack of a focal necrotic core allowed us to address the role of microglia response to trauma with only a limited influx of circulating adaptive and innate immune cells. We compared the injury-induced responses in WT mice and in p38a conditional KO mice where p38a is selectively deficient in cells of the myeloid linage: neutrophils/macrophages/microglia (p38a KO mice) (Kang et al., 2008; Bachstetter et al., 2011; Hume, 2011; Xing et al., 2011).

To assess motor function, we used the rotarod task, which is highly sensitive to vestibulomotor deficits associated with brain injury (Hamm, 2001). Adult mice were trained for 2 days on the rotarod task until all mice met criterion of 1 min at 4 rpm. From day 1 to day 7 after the diffuse brain injury, mice were tested on an accelerating rotarod (0–25 rpm over 5min). As shown in Figure 1A, injured WT mice showed a significant motor impairment following injury compared to the uninjured sham mice, whereas the p38a. KO mice did not exhibit any significant motor impairment after injury.

Synaptic protein levels in the cortex 7-days post injury were quantified to determine if the observed motor deficit was also associated with synaptic loss. We found that there was a decrease in PSD95 and synaptophysin protein levels following the diffuse brain injury in the WT mice, although the decrease in protein levels did not reach statistical significance as determined by a one-way ANOVA (Figure 1B). Interestingly, the injured microglia p38a KO mice showed no decrease in synaptic protein levels, and were indistinguishable from sham controls (Figure 1B).

Inflammatory cytokine and chemokine response peaks during the first 9-hours after diffuse brain injury

To determine the temporal changes in the inflammatory response following diffuse brain injury, we subjected male C57/BL6J mice to mFPI and then measured by real-time PCR a panel of cytokine, chemokine, microglia and astrocyte markers in the cortex at select time points following the injury (Figure 2). Cytokines and chemokines were found to peak between 3-hours and 9-hours after the injury (Figure 2A). Two markers associated with the alternative activation state (M2) microglia phenotype, arg1 and YM1, were found to be strongly increased by 9-hours; however, by 7-days the expression of the M2 markers was below the sham level (Figure 2B). The diffuse brain injury had a limited effect on astrocyte markers, with the exception of GFAP and vimentin (VIM) (Figure 2C).

Microglia continue to express p-p38 α for at least 7 days after a diffuse brain injury

Our previous work strongly implicates p38 α in the IL-1 β and TNF α response from microglia evoked by inflammatory stimuli (Bachstetter et al., 2011). As the peak cytokine response was found to occur between 3-to-9 hours after the diffuse brain injury, we

predicted that at ~ 6-hours after the injury we would see elevated p-p38a in the injured brain. Figure 3A shows the result of p-p38 IHC in mice 6-hours and 7-days after the mFPI. In the WT mFPI mice, p-p38⁺ cells were found throughout the injured cortex at 6-hours, with a similar number of p-p38⁺ cells found at 7-days after the diffuse TBI. In contrast, p-p38⁺ cells were nearly absent in the p38a KO mFPI mice (Figure 3B). IHC for p-p38 is not specific for cell type or p38 isotype. However, the observation that the p38a KO mice show essentially no p-p38 staining further validates the KO, and provides support that following a diffuse TBI it is myeloid cells, presumably microglia, and the alpha isoform of p38 that is responsible for the p-p38 increase seen following injury.

Microglia activation in response to a diffuse TBI is dependent on p38α MAPK

Microglia, the resident tissue immune effector cells of the CNS, rapidly respond to tissue trauma by altering their morphology and moving to the site of injury (Davalos et al., 2005). The intracellular signal transduction that regulates this response is not fully known. We have previously reported in rats that the mFPI model induces a classical activation of microglia using IBA1 (Cao et al., 2012). This activation of microglia after mFPI without tissue loss provided us with the opportunity to probe the intracellular pathways involved in the microglia morphological response using an *in vivo* disease relevant injury model. Figure 4A shows the result of IBA1 IHC in mice 6-hours and 7-days after the mFPI. In the shaminjured mice, a uniform spatial distribution of the IBA1⁺ microglia, characteristic of quiescent phenotype, was seen in the sham mice at both time points. Following the brain injury in WT mice, there was a strong morphological activation of the IBA1⁺ cells, including large multicellular groups, or clusters, of microglia. Quantification of the intensity of the IBA1 immunoreactivity throughout the neocortex demonstrated a significant increase in IBA1 staining in the injured WT mice compared with the injured p38a KO mice (Figure 4B). IHC for CD68, a macrophage marker associated with phagocytic cells (da Silva and Gordon, 1999; Kurushima et al., 2000), also clearly showed an up-regulation at 6-hours and 7-days post-injury in WT mice (Figure 4C). In contrast, the p38a KO mice failed to show increased CD68⁺ staining after the injury (Figure 4D).

As shown in Figure 5, by 6-hours post-injury in the WT mice, a strong increase in the IBA1 immunoreactivity was found, the uniform microglia distribution was lost, and the cells formed clusters where the individual cell processes become indistinguishable by light microscopy. In some instances the morphology of the microglia took on a rod shape perpendicular to the cortex (Figure 5A–B) (Cao et al., 2012; Ziebell et al., 2012). At times the clusters of microglia appeared to take on the shape of a layer-V pyramidal neuron (Figure 5C). Microglia in the WT mice at 6-hours post-injury were also found to have processes with large swellings (Figure 5D). In the p38a KO mice, at 6-hours post-injury, these unusual microglia morphologies were not observed (Figure 5E–F). Instead, microglia in the injured p38a KO mice were found to have thin highly ramified processes similar to the sham mice (Figure 5G), and in stark contrast to the injured WT mice. Using the Aperio nuclear algorithm, we quantified the number of microglia clusters 6-hr post-injury and found that the p38a was necessary for the microglia to form multicellular clusters (Figure 5H–J).

Suppression of the acute pro-inflammatory response following a diffuse traumatic brain injury requires $p38\alpha$ in myeloid cells

Previously we have found, in a diffuse TBI model, a surge of proinflammatory cytokines occurs within the first 12 hours, which is important for subsequent cognitive impairments (Lloyd et al., 2008). Using *in vitro* assays, we have also found that p38a is a key intracellular signaling kinase in microglia involved in the production of proinflammatory cytokines (Bachstetter et al., 2011). Therefore, we hypothesized that microglia p38a is critical for the cytokine surge following a diffuse brain injury. However, unexpectedly and

contrary to our hypothesis, we found elevated levels of the proinflammatory cytokines IL-1 β , IL-6, TNF α (Figure 6A) and the chemokines CCL2, CCL5, CXCL1 (Figure 6B) in the cortex of p38 α KO mice 6 hours after the injury compared to the sham-injured and WT mFPI mice. Interestingly, by 7-days after the injury the levels of IL-1 β remained significantly elevated in the WT mFPI mice, but were back to basal in the p38 α KO mFPI mice (Figure 6A). The levels of the other cytokines and chemokines were also low to undetected by 7-days post-injury in WT and p38 α KO mice.

Gene expression changes reveal increased M1 cytokine/chemokine and heightened M2 response in the p38 α KO mice at 6-hours post injury

To begin to explore the mechanism by which the acute pro-inflammatory response is increased in the KO mice, we measured a panel of cytokine, chemokine, microglia and astrocyte markers by real-time PCR. As shown in Figure 7A, a significant increase was seen in the expression of proinflammatory cytokines IL-1 β , TNFa and the chemokines CCL2, CCL3 in the cortex of p38a KO mice 6 hours after the injury compared to the injured WT and sham-injured mice, replicating the changes in cytokines and chemokines seen at the protein level. By 7-days after the injury, the levels of IL-1 β expression in the KO mice were found to be significantly less than that of the WT mice (Figure 7A). Interestingly, we also found that at 6-hours after the injury, KO mice had a more robust M2 response, as shown by elevated expression of the M2 markers arg1 and YM1, although the increase did reach statistical significance as determined by a one-way ANOVA (Figure 7B). Whether these effects are solely from microglia remains to be shown. Few changes were seen in the expression of astrocyte markers following the diffuse brain injury at either time point. However, we did find that at 6-hours after the injury the expression of GFAP and VIM was significantly increased in the KO mice compared to the WT mice (Figure 7C).

Astrogliosis remains intact in p38a KO mice following a diffuse TBI

As we found increased expression of GFAP and VIM in the p38a KO mice, we sought to determine if there might be an increasing astrogliosis that may account for the acute increase in cytokines seen in the p38a KO mice. Therefore, we performed IHC for GFAP, a marker of astrocytes, which in the mouse is normally found expressed at low levels in the cortex. As shown in Figure 8, in the sham-injured mice, very little GFAP staining was seen in the cortex. The diffuse TBI caused a strong astrogliosis, which was most evident at 7-days post-injury when injured mice showed a robust increase in GFAP staining regardless of genotype (Figure 8A). Quantification of staining in the cortex demonstrated that the p38a KO mice had significantly less GFAP staining at 6-hours post-injury compared to the injured WT mice. By 7-day post-injury there was no detectable difference in GFAP staining between the injured WT or p38a KO mice (Figure 8A,B).

The number of infiltrating innate immune cell do not account for the increase in cytokines seen in the KO mice following a diffuse TBI

CD45 is a transmembrane protein tyrosine phosphatase that is expressed on all nucleated hematopoietic cells (Penninger et al., 2001). The expression of CD45 on resident microglia is low but upon stimulation the expression of CD45 on microglia is upregulated (Sedgwick et al., 1991), and high expression of CD45 as determined by flow cytometry is associated with infiltrating macrophages (Mizutani et al., 2012). Figure 9A shows representative photomicrographs of the CD45 IHC. A significant increase in CD45 staining was seen in the cortex of injured WT mice, but a much more limited increase in CD45 staining in the p38a. KO mice (Figure 9B).

Previous studies have suggested that macrophages are necessary to limit the number of neutrophils following trauma (Lucas et al., 2010), by regulating neutrophil recruitment and

clearance (Soehnlein and Lindbom, 2010). As a myeloid cell, neutrophils would also be deficient in p38a in the KO mouse model; therefore, we quantified the number of GR1+ cells in the cortex to determine if there was an increase in number of neutrophils. We found a significant increase (p<0.05) in the number of GR1⁺ cells in the cortex following diffuse brain injury in WT mice; however, there was no difference between the injured WT or p38a KO mice in the number of GR1⁺ cells (Figure 9C). This suggests that neutrophil recruitment following the diffuse brain injury is independent of p38a, as we do not see a difference in the number of GR1⁺ cells. In contrast, the activation and/or recruitment of macrophage/ microglia following the diffuse brain injury is p38a dependent, as there is less CD45 staining in the KO mice. Our data clearly show that the numbers of CD45⁺ cells and GR1⁺ cells are either decreased or the same in the p38a. KO mice, and therefore an increased number of infiltrating immune cells is not the mechanism for the increase in cytokines seen in the KO mice. However, it should be noted that determining the number of CD45+ cells and GR1+ cells alone does not rule out the possibility that the activation state and/or ratio of the infiltrating monocytes/ macrophages versus brain-resident microglia may differ in the p38 WT or KO mice and that there may be qualitative differences in the responsiveness caused by the lack of p38a in the cells that do infiltrate.

DISCUSSION

In the present study, we have identified p38a as a critical component in the intracellularsignaling mechanisms by which a diffuse brain injury leads to activation of microglia. Moreover, we found that p38a has an important role in perpetuating injury-induced microglia activation, despite the fact that acutely p38a suppresses the peak cytokine response to diffuse brain injury. We propose a model (Figure 10) where the hypertrophy and directional chemotaxis of microglia following a brain injury are dependent on p38a. In the absence of p38a, there is a failure of microglia priming such that the enhanced level of cytokines seen in the p38a KO mice does not produce microglia activation or chronically elevated cytokines. Therefore, microglia priming by p38a is important to preserve a state of chronic neuroinflammation following a diffuse brain injury; inhibition or elimination of p38a can improve outcome.

Microglia are known to respond rapidly (30 min) and migrate to the source of injury (Davalos et al., 2005; Nimmerjahn et al., 2005). The signal transduction mechanisms in microglia that lead to this response are poorly understood, yet there is strong support for the involvement of p38 in chemotaxis (Heit et al., 2002; Heit et al., 2008), with chemoattractant selectivity (i.e. complement C5a) not being p38a dependent (Isfort et al., 2011), while IL-1β is p38 dependent (Ferreira et al., 2012)). Dead, dying, and injured cells release 'find me' and 'eat me' signals that attract microglia and macrophages to isolate the damage and remove the dead cells (Ravichandran, 2011). Purinergic signaling is the most well described chemoattractant in the CNS (Davalos et al., 2005; Nimmerjahn et al., 2005; Haynes et al., 2006). ATP has been shown to increase levels of phospho-p38 in microglia (Trang et al., 2009). However, the role of p38 in chemotaxis to ATP is not clear, as chemotaxis to ATP has been reported to be both dependent (Heit et al., 2008) and independent of p38 (Isfort et al., 2011). This may be due to differences in chemoattractant signals that activate microglia distally (chemokines) vs. chemoattractant signals at the end target, and most likely involves an integration of these signals. In complex gradients of chemoattractants, p38 and PI3K can have opposing roles in the distal vs. end target movement, with p38 important for movement towards end target (Heit et al., 2008). Our data suggest that p38 may participate in the integration of the chemoattractant signals following the injury. At 6 hours after the diffuse brain injury, we found a striking activation of microglia, with a loss of the normal spatial distribution, clustering of multiple cells around presumably injured neurons and blood vessels, and the appearance of processes with swollen inclusions. In injured mice where

p38a is deficient in microglia, we found only a limited increase in microglia reactivity, at both 6 hours and 7 days after the injury, and failure of microglia to form multicellular clusters. We also found very limited CD45 staining in the injured p38a KO mice, which could represent a decreased level of macrophage infiltration.

Microglia are known to phagocytosis dying cells (Katayama et al., 2012), myelin and axonal debris (Tanaka et al., 2009; Ghasemlou et al., 2010), misfolded proteins (Reed-Geaghan et al., 2009), and synapses in response to injury such as ischemia (Wake et al., 2009), or as an activity dependent synaptic pruning process (Schafer et al., 2012). In many instances this process has been shown to be p38 dependent (Reed-Geaghan et al., 2009; Tanaka et al., 2009; Ghasemlou et al., 2010; Katayama et al., 2012). Therefore, the failure of microglia to activate and form multicellular clusters may reflect failure to activate a p38-dependent phagocytosis response, which is supported by the diminished CD68 response seen in the injured p38a KO mice.

In the diffuse brain injury model employed in this study, previous reports demonstrate axonal injury, but lack neuronal death. Moreover, the injured neurons in this model show signs of axonal regeneration and recovery with the peak of the neuron injury response occurring during the first 7 days and partial recovery over the subsequent month (Singleton et al., 2002; Greer et al., 2011; Greer et al., 2012), suggesting that while these neurons are endangered they are salvageable. Our data suggest that limiting the microglia response to the injury is potentially beneficial, as shown by the lack of motor impairments in the p38a KO mice. The clearance of axonal debris, which *in vitro* is p38 dependent, is beneficial for the promotion of axonal growth (Hosmane et al., 2012). However, if the axon was damaged, but not beyond repair, clearance of this axon would be detrimental. Therefore, regulating the microglia response and/or p38 signaling in a mild brain injury may produce a significantly different outcome than in a TBI with pronounced neuronal death or blood brain barrier damage.

Evidence from clinical studies and preclinical animal models suggest the key role of proinflammatory cytokine overproduction from activated glia as a potential driving force for pathology progression in TBI (Schmidt et al., 2005; Kelley et al., 2006; Lloyd et al., 2008; Cao et al., 2012). One of the most striking findings of our study was the demonstration that the inflammatory cytokine response in the CNS, which dogmatically has been associated with the activation of microglia, can be clearly disconnected from the microglia activation via a p38a dependent mechanism following a diffuse brain injury. The seemingly divergent reaction to the diffuse brain injury, i.e. a robust increase in acute cytokine response with a lack of microglia activation in the p38a conditional KO mice, distinctly shows that microglia activation, as determined morphologically, does not necessitate the production of cytokines, and vice versa. Nevertheless, our data suggest that if microglia are incapable of responding to the acute phase cytokine response, because of a lack of p38a, then the increase in cytokines does not lead to chronic or enhanced neuroinflammation and subsequent synaptic and behavioral impairments.

Although p38 α is undoubtedly important in the production of proinflammatory cytokines (Bachstetter et al., 2011), it is becoming apparent that p38 α also activates negative feedback pathways that limit the production of proinflammatory cytokines (for review see (Bachstetter and Van Eldik, 2010)). The evolutionary importance of a tightly regulated immune response is exemplified by the numerous known ways and potential yet undiscovered ways that the inflammatory response is self-limiting. It has previously been demonstrated in a variety of cell types that p38 can antagonize JNK, ERK and NF κ B signaling (Zhang et al., 2001; Mathur et al., 2004; Gorska et al., 2007; Heinrichsdorff et al., 2008; Kim et al., 2008). One well-described mechanism of negative feedback is the dual-

specificity protein phosphatase 1 (DUSP1), which dephosphorylates both phosphothreonine and phosphotyrosine residues to inactivate p38 and JNK (Liu et al., 2007). The expression of DUSP1 is induced by p38 and ERK via a CREB-binding site in the promoter of DUSP1 (Sommer et al., 2000). In addition, p38a has been shown to block the phosphorylation of ERK by a direct interaction (Zhang et al., 2001). Therefore, the increase in proinflammatory cytokines we see at 6hr in the p38a KO mice could be a result of prolonged JNK activation; more work is necessary to test this hypothesis.

Previous studies report increased levels of p38 after TBI and spinal cord injury (SCI) (Mori et al., 2002; Xu et al., 2006; Stirling et al., 2008; Ghasemlou et al., 2010) However, preclinical experiments using small molecule p38 inhibitors have demonstrated mixed results, with a lack of neuroprotection following a focal TBI (Mori et al., 2002), or moderate SCI (Stirling et al., 2008), while showing protection in a mild SCI (Xu et al., 2006). A recent study using mice deficient in MK2, a direct downstream substrate of p38, demonstrated reduced inflammation and improved locomotor recovery following SCI (Ghasemlou et al., 2010). These results are in agreement with our current study, which implicates p38 as important for regulating inflammation as part of the repair process to injury. However, inflammation is also critical to the repair process, and depending on the type and severity of the injury, inhibiting the p38-MK2 pathway can slow wound healing (Thuraisingam et al., 2010). Nevertheless, in a sterile environment, such as the CNS, suppressing the secondary injury response leading to the chronic inflammatory sequelae via the p38 pathway can be neuroprotective as demonstrated in preclinical models of ischemia (Barone et al., 2001; Legos et al., 2001; Wang et al., 2002), Alzheimer's disease (Culbert et al., 2006; Munoz et al., 2007), and Parkinson's disease (Thomas et al., 2008). While the p38 pathway appears to be a promising clinical target for the treatment of CNS disorders with dysregulated neuroinflammatory responses, more studies are still necessary, to determine therapeutic window, dosing, long-term efficacy, and improve the pharmacodynamics and selectivity of small molecule p38 inhibitors. In summation, our study demonstrates that p38a is a critical intracellular signaling molecule in microglia regulation of the inflammatory repair process following a diffuse TBI.

Acknowledgments

We thank Edgardo Dimayuga, Jordan Harrison, Janna Neltner, and Bin Xing for their assistance with various aspects of this work. This research was supported in part by funds from the Alzheimer's Association Zenith award (LVE) and NIH grants R01 NS064247 (LVE), R01 NS065052 (JL), R21 NS072611 (JL), R01 NS065052-S (JL), and F32 AG037280 (ADB). We are grateful to Dr. Huiping Jiang at Boehringer Ingelheim Pharmaceuticals, Inc. and Dr. Jiahuai Han at The Scripps Research Institute for the kind gifts of the knockout mice.

REFERENCES

- Bachstetter AD, Van Eldik LJ. The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS. Aging Dis. 2010; 1:199–211. [PubMed: 22720195]
- Bachstetter AD, Xing B, de Almeida L, Dimayuga ER, Watterson DM, Van Eldik LJ. Microglial p38alpha MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Abeta). J Neuroinflammation. 2011; 8:79. [PubMed: 21733175]
- Bachstetter AD, Norris CM, Sompol P, Wilcock DM, Goulding D, Neltner JH, St Clair D, Watterson DM, Van Eldik LJ. Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology. J Neurosci. 2012; 32:10201–10210. [PubMed: 22836255]
- Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, White RF, McVey MJ, Legos JJ, Erhardt JA, Nelson AH, Ohlstein EH, Hunter AJ, Ward K, Smith BR, Adams JL, Parsons AA. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain

injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther. 2001; 296:312–321. [PubMed: 11160612]

- Cao T, Thomas TC, Ziebell JM, Pauly JR, Lifshitz J. Morphological and genetic activation of microglia after diffuse traumatic brain injury in the rat. Neuroscience. 2012; 225:65–75. [PubMed: 22960311]
- Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010; 10:826–837. [PubMed: 21088683]
- Clarke S, Greaves DR, Chung LP, Tree P, Gordon S. The human lysozyme promoter directs reporter gene expression to activated myelomonocytic cells in transgenic mice. Proc Natl Acad Sci U S A. 1996; 93:1434–1438. [PubMed: 8643649]
- Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999; 8:265–277. [PubMed: 10621974]
- Colton CA. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol. 2009; 4:399–418. [PubMed: 19655259]
- Culbert AA, Skaper SD, Howlett DR, Evans NA, Facci L, Soden PE, Seymour ZM, Guillot F, Gaestel M, Richardson JC. MAPK-activated protein kinase 2 deficiency in microglia inhibits proinflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2006; 281:23658–23667. [PubMed: 16774924]
- da Silva RP, Gordon S. Phagocytosis stimulates alternative glycosylation of macrosialin (mouse CD68), a macrophage-specific endosomal protein. Biochem J. 1999; 338(Pt 3):687–694.
 [PubMed: 10051440]
- Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005; 8:752–758. [PubMed: 15895084]
- David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci. 2011; 12:388–399. [PubMed: 21673720]
- Ferreira R, Santos T, Cortes L, Cochaud S, Agasse F, Silva AP, Xapelli S, Malva JO. Neuropeptide Y inhibits interleukin-1 beta-induced microglia motility. J Neurochem. 2012; 120:93–105. [PubMed: 22007767]
- Gavett BE, Stern RA, Cantu RC, Nowinski CJ, McKee AC. Mild traumatic brain injury: a risk factor for neurodegeneration. Alzheimers Res Ther. 2010; 2:18. [PubMed: 20587081]
- Ghasemlou N, Lopez-Vales R, Lachance C, Thuraisingam T, Gaestel M, Radzioch D, David S. Mitogen-activated protein kinase-activated protein kinase 2 (MK2) contributes to secondary damage after spinal cord injury. J Neurosci. 2010; 30:13750–13759. [PubMed: 20943915]
- Giunta B, Obregon D, Velisetty R, Sanberg PR, Borlongan CV, Tan J. The immunology of traumatic brain injury: a prime target for Alzheimer's disease prevention. J Neuroinflammation. 2012; 9:185. [PubMed: 22849382]
- Gorska MM, Liang Q, Stafford SJ, Goplen N, Dharajiya N, Guo L, Sur S, Gaestel M, Alam R. MK2 controls the level of negative feedback in the NF-kappaB pathway and is essential for vascular permeability and airway inflammation. J Exp Med. 2007; 204:1637–1652. [PubMed: 17576778]
- Greer JE, McGinn MJ, Povlishock JT. Diffuse traumatic axonal injury in the mouse induces atrophy, c-Jun activation, and axonal outgrowth in the axotomized neuronal population. J Neurosci. 2011; 31:5089–5105. [PubMed: 21451046]
- Greer JE, Povlishock JT, Jacobs KM. Electrophysiological abnormalities in both axotomized and nonaxotomized pyramidal neurons following mild traumatic brain injury. J Neurosci. 2012; 32:6682–6687. [PubMed: 22573690]
- Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008; 453:314–321. [PubMed: 18480812]
- Hamm RJ. Neurobehavioral assessment of outcome following traumatic brain injury in rats: an evaluation of selected measures. J Neurotrauma. 2001; 18:1207–1216. [PubMed: 11721739]


- Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan W-B, Julius D. The P2Y(12) receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci. 2006; 9:1512–1519. [PubMed: 17115040]
- Heinrichsdorff J, Luedde T, Perdiguero E, Nebreda AR, Pasparakis M. p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep. 2008; 9:1048–1054. [PubMed: 18704119]
- Heit B, Tavener S, Raharjo E, Kubes P. An intracellular signaling hierarchy determines direction of migration in opposing chemotactic gradients. J Cell Biol. 2002; 159:91–102. [PubMed: 12370241]
- Heit B, Robbins SM, Downey CM, Guan Z, Colarusso P, Miller BJ, Jirik FR, Kubes P. PTEN functions to 'prioritize' chemotactic cues and prevent 'distraction' in migrating neutrophils. Nat Immunol. 2008; 9:743–752. [PubMed: 18536720]
- Hosmane S, Tegenge MA, Rajbhandari L, Uapinyoying P, Kumar NG, Thakor N, Venkatesan A. Toll/ interleukin-1 receptor domain-containing adapter inducing interferon-beta mediates microglial phagocytosis of degenerating axons. J Neurosci. 2012; 32:7745–7757. [PubMed: 22649252]
- Huang G, Wang Y, Vogel P, Kanneganti TD, Otsu K, Chi H. Signaling via the kinase p38alpha programs dendritic cells to drive TH17 differentiation and autoimmune inflammation. Nat Immunol. 2012; 13:152–161. [PubMed: 22231518]
- Hume DA. Applications of myeloid-specific promoters in transgenic mice support in vivo imaging and functional genomics but do not support the concept of distinct macrophage and dendritic cell lineages or roles in immunity. J Leukoc Biol. 2011; 89:525–538. [PubMed: 21169519]
- Isfort K, Ebert F, Bornhorst J, Sargin S, Kardakaris R, Pasparakis M, Bahler M, Schwerdtle T, Schwab A, Hanley PJ. Real-time imaging reveals that P2Y2 and P2Y12 receptor agonists are not chemoattractants and macrophage chemotaxis to complement C5a is phosphatidylinositol 3-kinase (PI3K)- and p38 mitogen-activated protein kinase (MAPK)-independent. J Biol Chem. 2011; 286:44776–44787. [PubMed: 22057273]
- Johnson VE, Stewart W, Smith DH. Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol. 2012; 22:142–149. [PubMed: 21714827]
- Kang YJ, Chen J, Otsuka M, Mols J, Ren S, Wang Y, Han J. Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation. J Immunol. 2008; 180:5075– 5082. [PubMed: 18354233]
- Katayama T, Kobayashi H, Okamura T, Yamasaki-Katayama Y, Kibayashi T, Kimura H, Ohsawa K, Kohsaka S, Minami M. Accumulating Microglia Phagocytose Injured Neurons in Hippocampal Slice Cultures: Involvement of p38 MAP Kinase. PLoS One. 2012:7.
- Kelley BJ, Lifshitz J, Povlishock JT. Neuroinflammatory responses after experimental diffuse traumatic brain injury. J Neuropathol Exp Neurol. 2007; 66:989–1001. [PubMed: 17984681]
- Kelley BJ, Farkas O, Lifshitz J, Povlishock JT. Traumatic axonal injury in the perisomatic domain triggers ultrarapid secondary axotomy and Wallerian degeneration. Exp Neurol. 2006; 198:350– 360. [PubMed: 16448652]
- Kim C, Sano Y, Todorova K, Carlson BA, Arpa L, Celada A, Lawrence T, Otsu K, Brissette JL, Arthur JS, Park JM. The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol. 2008; 9:1019– 1027. [PubMed: 18677317]
- Kurushima H, Ramprasad M, Kondratenko N, Foster DM, Quehenberger O, Steinberg D. Surface expression and rapid internalization of macrosialin (mouse CD68) on elicited mouse peritoneal macrophages. J Leukoc Biol. 2000; 67:104–108. [PubMed: 10648004]
- Legos JJ, Erhardt JA, White RF, Lenhard SC, Chandra S, Parsons AA, Tuma RF, Barone FC. SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Brain Res. 2001; 892:70–77. [PubMed: 11172750]
- Lifshitz, J. Fluid percussion injury. In: Chen, J., editor. Animal Models of Acute Neurological Injuries. Totowa, NJ: Humana Press; 2008. p. 369-384.
- Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases--regulating the immune response. Nat Rev Immunol. 2007; 7:202–212. [PubMed: 17318231]
- Lloyd E, Somera-Molina K, Van Eldik LJ, Watterson DM, Wainwright MS. Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel

small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J Neuroinflammation. 2008; 5:28. [PubMed: 18590543]

- Lucas T, Waisman A, Ranjan R, Roes J, Krieg T, Muller W, Roers A, Eming SA. Differential roles of macrophages in diverse phases of skin repair. J Immunol. 2010; 184:3964–3977. [PubMed: 20176743]
- Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med. 2004; 10:540–544. [PubMed: 15107845]
- Mizutani M, Pino PA, Saederup N, Charo IF, Ransohoff RM, Cardona AE. The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol. 2012; 188:29–36. [PubMed: 22079990]
- Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T. Modulation of immune response by head injury. Injury. 2007; 38:1392–1400. [PubMed: 18048036]
- Mori T, Wang X, Jung JC, Sumii T, Singhal AB, Fini ME, Dixon CE, Alessandrini A, Lo EH. Mitogen-activated protein kinase inhibition in traumatic brain injury: in vitro and in vivo effects. J Cereb Blood Flow Metab. 2002; 22:444–452. [PubMed: 11919515]
- Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, McNamara LK, Chico LW, Van Eldik LJ, Watterson DM. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation. 2007; 4:21. [PubMed: 17784957]
- Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005; 308:1314–1318. [PubMed: 15831717]
- Penninger JM, Irie-Sasaki J, Sasaki T, Oliveira-dos-Santos AJ. CD45: new jobs for an old acquaintance. Nat Immunol. 2001; 2:389–396. [PubMed: 11323691]
- Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, Kinnunen KM, Gentleman S, Heckemann RA, Gunanayagam K, Gelosa G, Sharp DJ. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011; 70:374–383. [PubMed: 21710619]
- Ravichandran KS. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity. 2011; 35:445–455. [PubMed: 22035837]
- Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci. 2009; 29:11982–11992. [PubMed: 19776284]
- Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT, Workshop Scientific T, Advisory Panel M. Classification of traumatic brain injury for targeted therapies. J Neurotrauma. 2008; 25:719–738. [PubMed: 18627252]
- Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012; 74:691–705. [PubMed: 22632727]
- Schmidt OI, Heyde CE, Ertel W, Stahel PF. Closed head injury--an inflammatory disease? Brain Res Brain Res Rev. 2005; 48:388–399. [PubMed: 15850678]
- Sedgwick JD, Schwender S, Imrich H, Dorries R, Butcher GW, ter Meulen V. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci U S A. 1991; 88:7438–7442. [PubMed: 1651506]
- Singleton RH, Zhu J, Stone JR, Povlishock JT. Traumatically induced axotomy adjacent to the soma does not result in acute neuronal death. J Neurosci. 2002; 22:791–802. [PubMed: 11826109]
- Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol. 2010; 10:427–439. [PubMed: 20498669]
- Sommer A, Burkhardt H, Keyse SM, Luscher B. Synergistic activation of the mkp-1 gene by protein kinase A signaling and USF, but not c-Myc. FEBS Lett. 2000; 474:146–150. [PubMed: 10838075]
- Stirling DP, Liu J, Plunet W, Steeves JD, Tetzlaff W. SB203580, a p38 mitogen-activated protein kinase inhibitor, fails to improve functional outcome following a moderate spinal cord injury in rat. Neuroscience. 2008; 155:128–137. [PubMed: 18562123]

- Sudduth TL, Wilson JG, Everhart A, Colton CA, Wilcock DM. Lithium treatment of APPSwDI/ NOS2–/– mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS One. 2012; 7:e31993. [PubMed: 22347510]
- Tanaka T, Ueno M, Yamashita T. Engulfment of Axon Debris by Microglia Requires p38 MAPK Activity. J Biol Chem. 2009; 284:21626–21636. [PubMed: 19531468]
- Thomas T, Timmer M, Cesnulevicius K, Hitti E, Kotlyarov A, Gaestel M. MAPKAP kinase 2deficiency prevents neurons from cell death by reducing neuroinflammation--relevance in a mouse model of Parkinson's disease. J Neurochem. 2008; 105:2039–2052. [PubMed: 18298661]
- Thuraisingam T, Xu YZ, Eadie K, Heravi M, Guiot MC, Greemberg R, Gaestel M, Radzioch D. MAPKAPK-2 signaling is critical for cutaneous wound healing. J Invest Dermatol. 2010; 130:278–286. [PubMed: 19609314]
- Trang T, Beggs S, Wan X, Salter MW. P2X4-Receptor-Mediated Synthesis and Release of Brain-Derived Neurotrophic Factor in Microglia Is Dependent on Calcium and p38-Mitogen-Activated Protein Kinase Activation. J Neurosci. 2009; 29:3518–3528. [PubMed: 19295157]
- Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, Lee VM, Trojanowski JQ, Smith DH. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol. 2007; 208:185–192. [PubMed: 17826768]
- Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci. 2009; 29:3974–3980. [PubMed: 19339593]
- Wang X, Xu L, Wang H, Young PR, Gaestel M, Feuerstein GZ. Mitogen-activated protein kinaseactivated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice. J Biol Chem. 2002; 277:43968–43972. [PubMed: 12215446]
- Xing B, Bachstetter AD, Eldik LJ. Microglial p38alpha MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFalpha. Mol Neurodegener. 2011; 6:84. [PubMed: 22185458]
- Xu Z, Wang BR, Wang X, Kuang F, Duan XL, Jiao XY, Ju G. ERK1/2 and p38 mitogen-activated protein kinase mediate iNOS-induced spinal neuron degeneration after acute traumatic spinal cord injury. Life Sci. 2006; 79:1895–1905. [PubMed: 16978658]
- Zhang H, Shi X, Hampong M, Blanis L, Pelech S. Stress-induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase. J Biol Chem. 2001; 276:6905–6908. [PubMed: 11238443]
- Ziebell JM, Taylor SE, Cao T, Harrison JL, Lifshitz J. Rod microglia: elongation, alignment, and coupling to form trains across the somatosensory cortex after experimental diffuse brain injury. J Neuroinflammation. 2012; 9:247. [PubMed: 23111107]

A: rotarod



B: synaptic protein levels






Figure 1. Myeloid-specific deletion of p38a protects mice from diffuse brain injury induced vestibulomotor impairments and synaptic protein loss

(A) Injured WT mice (mFPI WT) demonstrated significant impairments in rotarod performance compared to sham injured mice and mFPI p38 α KO mice. The injured KO mice were not significantly different from the sham mice. (B) While the differences did not reach statistical significance, at 7 days post injury, levels of the synaptic proteins PSD95 and synaptophysin (SYP) were decreased in the WT mice compared to sham, whereas the injury induced decrease was not seen in the KO mice. (*p<0.05, **p<0.01 sham vs. mFPI WT; #p<0.05 mFPI WT vs. mFPI KO) (n=8–14 per group).

A: cytokine / chemokine












Figure 2. Changes in gene expression associated with glial activation after diffuse brain injury Temporal changes in cytokine/chemokine (**A**), microglia (**B**), and astrocyte markers (**C**) were measured in the cortex of male C57BL/6J mice subjected to sham conditions (gray), or at 3h (red), 9h (green), 24h (blue) or 7days (black) after mFPI (n=3 per time point).




Figure 3. The increase in p-p38 following diffuse brain injury is associated with myeloid cells (A) p-p38 immunohistochemistry was seen in the WT mFPI mice at 6-hours and 7-days after injury, but was nearly absent in the sham injured mice and the p38a. KO mFPI mice. (B) Quantification shows a significant increase in the number of p-p38+ cells in the injured WT mice at 6hr, which persists to 7-days post injury. Injured p38a. KO mice show little to no p-p38 immunoreactivity and are not different from sham injured mice at either time point (n=6-12 per group) (*p<0.05; **p<0.01).




Figure 4. p38a KO microglia fail to respond morphologically to a diffuse brain injury (**A**) IBA1 immunohistochemistry shows a strong increase in staining and morphological alterations in the WT mFPI mice post-injury (p.i.), which were absent in the KO mFPI mice 6 hours after injury, and remained diminished in the KO mice 7-days after injury. Arrows show clusters of microglia around what appears to be a blood vessel. (**B**) Quantification shows a significant increase in IBA1 staining in the injured WT mice at 6hr, which persists to 7-days post injury. Microglia in the KO mice demonstrated a failure to activate during the acute (6hr) or chronic phase (7d) after the injury. (**C**) CD68 immunohistochemistry further supports the lack of a microglia morphological response to the diffuse brain injury in the

absence of p38 α , both at acute time points and during the chronic phase after the injury. (**D**) Quantification shows a significant increase in CD68 staining in the WT injured mice at 6hr that persisted to 7-days post injury, with minimal response in the KO mice. Data are presented as % of sham (n=6–8 per group). (*p<0.05; **p<0.01).





Figure 5. Microglia clustering is dependent on p38a KO following a diffuse TBI (**A–D**) IBA1 immunohistochemistry shows the spectrum of microglia activation seen in the WT mice 6hr after the diffuse brain injury. Note the long rod shape microglia (**A**), trains of multiple microglia in plane with the axonal columns in the cortex (**B**), and multiple microglia in the shape of a layer-V pyramidal cell (**C**), as well as IBA1⁺ cells with retracted processes with large swellings (**D**). In contrast, the p38a KO mice exhibited thin ramified microglia processes (**E**), or looked morphologically similar (**F**) to sham injured mice (**G**). A cluster of microglia from a WT mFPI mouse shows the IBA1 staining (**H**), and the Aperio nuclear algorithm generated markup shows the reliable detection of the microglia clusters

(demonstrated here as the black markup) and not individual cells (arrows) (**I**). Quantification shows a significant increase in IBA1 clusters in the WT injured mice at 6hr post injury (**J**). Data are presented as % of sham (n=6–8 per group). (*p<0.05)

A: pro-inflammatory cytokine levels in cortex



B: chemokine levels in cortex






Figure 6. Cytokine and chemokine levels are acutely enhanced in the p38a KO mice following a diffuse brain injury

The protein levels of a panel of inflammatory cytokines (**A**) and chemokines (**B**) were measured in the neocortex by MSD multiplex immunoassay. The injured p38a KO mice were found to have significantly enhanced cytokine response at 6hrs, but by 7-days post-injury the cytokine response in the KO mice was below (IL-1 β) or equal to (IL-6) the response of the WT injured mice. The chemokines were also significantly increased at 6hrs in the p38a KO mice, and by 7-days the levels were near baseline. (n=6–12 per group) (**p<0.01; ***p<0.001).

A: cytokine / chemokine











Figure 7. Enhanced cytokine and chemokine gene expression is seen in the p38a KO mice at 6h after diffuse brain injury

Temporal changes in cytokine/chemokine (A), microglia (B), and astrocyte markers (C) were measured from the cortex harvested from sham mice (6h=gray; 7d=black), injured WT mice (6h=red; 7d=purple) or injured p38a KO mice (6h=blue; 7d=green). (n=4-10 per group) (**p<0.01 sham vs. mFPI WT; # p<0.05, ## p<0.01 mFPI WT vs. mFPI KO; ‡ p<0.05; ‡‡ p<0.01 sham vs. mFPI KO).






Figure 8. There is intact astrogliosis in myeloid-deficient p38a KO mice following injury (**A**) GFAP immunohistochemistry shows a strong increase in staining and morphological alterations in the WT mFPI mice 6hr post-injury, which was not as prominent in the p38a KO mFPI mice. By 7-days post-injury, WT and KO mice showed similar GFAP staining. (**B**) Quantification shows a significant increase in GFAP at 6hr after injury in WT mice but not KO mice. At 7 days there was no difference in astrogliosis between the WT and KO injured mice. Data are presented as % of sham (n=6–12 per group). (*p<0.05; **p<0.01) (## p<0.01 sham vs. mFPI KO, t-test).





Figure 9. Myeloid-deficient p38a. KO mice have a limited increase in CD45, but similar changes in GR1⁺ monocytes/neutrophils, compared to WT mice

(A) Representative photomicrographs of CD45⁺ immunohistochemistry in the cortex 6hr post injury. (B) A significant increase in CD45⁺ staining was found in the cortex of WT mFPI mice compared to sham-injured mice, whereas p38a KO mice showed very little increase in CD45⁺ staining. (C) The number of GR1⁺ cells were counted in the cortex and presented as the average number of GR1⁺ cells per coronal tissue section. WT and KO mice showed similar numbers of GR1⁺ cells after injury (n=6–12 per group) (*p<0.05; **p<0.01; ***p<0.001).








Figure 10. Proposed model of the role of p38a in the microglia response to diffuse brain injury (A)In WT mice, a mild-to-moderate diffuse brain injury induces a reactive glia response associated with elevated inflammatory cytokines and chemokines, morphological hypertrophy, and loss of microglia spatial domains as early as 6hr after injury. The reactive glia response, which is exemplified by a 'M1' proinflammatory phenotype, persists for at least 7 days after the injury. (B) In the p38a. KO mice, the acute phase cytokine response is elevated compared to the WT mice. However, despite the higher cytokine response, there is a failure of the microglia deficient in p38a to exhibit an acute or chronic phase

morphological activation response. (C) Our results suggest that p38a is a critical kinase in the detrimental inflammatory feed-forward loop responsible for neuromotor deficits.